Compare Stocks

AXMIN Inc., a gold exploration company, engages in the exploration and development of mineral properties in central and West Africa. Its primary asset is the Passendro gold project located in the Central African Republic. AXMIN Inc. is based in Vancouver, Canada.

Durango Resources Inc. engages in the acquisition and exploration of precious and base mineral resource properties in Canada. It holds 100% interest in a group of properties totaling approximately 9,500 hectares located in the Windfall Lake gold camp in the Abitibi region of Québec, Canada. The company was formerly known as Atocha Resources Inc. and changed its name to Durango Resources Inc. in February 2013. Durango Resources Inc. was incorporated in 2006 and is headquartered in Richmond, Canada.

Helios Advantage Income Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund seeks a high level of current income. The Fund seeks capital growth as a secondary investment objective. It invests a majority of its total assets in below-investment-grade debt securities. The Fund also may invest in investment grade debt securities, up to 15% of its total assets in foreign debt and foreign equity securities, and up to 25% of its total assets in domestic equity securities, including common and preferred stocks. The Fund invests in a range of below-investment-grade debt securities, including corporate bonds, mortgage-backed and asset-backed securities, and municipal and foreign government obligations, as well as securities of companies in bankruptcy reorganization proceedings or otherwise in the process of debt restructuring. The Fund's investment advisor is Brookfield Investment Management Inc.

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.